News
Displaying 211–220 of 504
-
Encouraging Early Report for Three Patients in LCA1-GUCY2D Gene Therapy Clinical Trial
Research NewsDevelopment of the emerging gene therapy is being funded by the Foundation’s RD Fund
-
Foundation Invests $5.5 Million in Seven New Translational Research Projects
Research NewsProjects target a variety of conditions including: age-related macular degeneration, Stargardt disease, retinitis pigmentosa, and Usher syndrome type 3A
-
Bionic Sight’s Optogenetic Therapy Enables Blind Patients to Detect Light and Motion in Early Trial
Research NewsThe approach holds potential for restoring vision to people with little or no vision
-
ProQR’s RNA Therapy for USH2A Performs Well in Phase 1/2 Clinical Trial
Research NewsThe company is planning two Phase 2/3 clinical trials for the treatment
-
Foundation Fighting Blindness Launches Chapter Program Rebrand
Foundation NewsThe program honors Lulie Gund and her legacy and commitment to the Foundation’s Chapter community.
-
Foundation’s No-Cost Program Increased Genetic Testing Rates for IRD Patients
Research NewsMore than 8,000 people have applied for genetic testing through the Foundation’s program
-
Foundation News
Course Title: Clinical Trials of Emerging Therapies for Retinal Degeneration Patients: Hope and Opportunities
-
A Eureka Moment for Paul Yang Boosts Advancement of Vision-Saving RP Drug
Research NewsHis latest Foundation grant is helping move the drug toward a clinical trial
-
Are You on the Clinical Trial Radar Screen?
Research NewsTherapy developers use the My Retina Tracker Registry to recruit for human studies of emerging therapies
-
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision
In the PressFormer Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of Luxturna™, to lead development of SparingVision’s proprietary asset, SPVN06, and further pipeline development
